Maravai Lifesciences Holdings, Inc. (MRVI)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance
Add to research

Current Price

as of Mar 12, 2025

$2.61

P/E Ratio

N/A

Market Cap

$611.12M

Mar 20, 2024Apr 24, 2024May 29, 2024Jul 2, 2024Aug 2, 2024Sep 5, 2024Oct 8, 2024Nov 11, 2024Dec 17, 2024Jan 24, 2025Mar 12, 2025$20.00$30.00$40.00$50.00
  • HRMY
Description
Add to research

Maravai Lifesciences Holdings, Inc. is a life sciences company. It is engaged in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm operates through the following segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. The Biologics Safety Testing segment focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.

Metrics
Add to research

Overview

  • HQSan Diego, CA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerMRVI
  • Price$2.61-1.14%

Trading Information

  • Market cap$611.12M
  • Float83.11%
  • Average Daily Volume (1m)4,760,800
  • Average Daily Volume (3m)2,789,275
  • EPS-$1.65

Company

  • Revenue$276.92M
  • Rev growth (1yr)-2.49%
  • Net income-$99.04M
  • Gross margin32.95%
  • EBITDA margin2.68%
  • EBITDA$1.75M
  • EV$1.43B
  • EV/Revenue5.15
  • P/EN/A
  • P/S1.33
  • P/B1.07
  • Debt/Equity162.56
Documents
Add to research